Compare Crowdstrike Holdings Inc (CRWD) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs DexCom, Inc. — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while DexCom, Inc. trades at $84.11 (market cap $31.86B). The key difference: Crowdstrike Holdings Inc is far larger — about 8.5× DexCom, Inc.'s market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and DexCom, Inc. for 62 Days on average.
| CRWD | DXCM | |
|---|---|---|
Market Cap | $269.31B | $31.86B |
Volume | 9,381,560 | 3,607,070 |
Sector | Technology | Health |
52-Week High | $278.86 | $92.34 |
52-Week Low | $87.56 | $54.84 |
Typical Hold Time | 97 Days | 62 Days |
Enterprise Value | $265.11B | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $263.01, down 0.92% on the day but near its 52-week high of $267.69. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings expectations in recent quarters. Revenue growth remains robust, reaching $3.95 billion in 2025, though profitability metrics show modest net income margins. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a consensus price target of $235.74.
CrowdStrike presents a compelling growth story with strong revenue expansion and AI-driven cybersecurity demand, but faces valuation concerns with elevated P/S and P/B ratios. The company's integration with OpenAI Marketplace and identity business growth provide catalysts, while competitive pressures and execution risks remain key considerations for investors.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
